FDA Letter API

Humble Juice Co. LLC

Letter data

Company
Humble Juice Co. LLC
Recipient
Daniel Clark | Humble Juice Co. LLC | 9400 Lurline Ave | Unit B-1 | Chatsworth | , | CA | 91311 | United States | daniel@humblejuiceco.com | info@humblejuiceco.com
Issue date
2021-04-09
Posted date
Not available
FDA office
Center for Tobacco Products
Subject
Not available
Product
Tobacco
CMS ID
583547
Reference number
RW1901097
FEI
Not available
Inspection dates
Not available

Normalized citations

21 CFR: None found

21 U.S.C.: None found

Related FDA links

No related FDA letter link is present in the source index.

Full source text

CLOSEOUT LETTER Humble Juice Co. LLC MARCS-CMS 583547 — April 09, 2021 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA UPS and Electronic Mail Reference #: RW1901097 Product: Tobacco Recipient: Recipient Name Daniel Clark Humble Juice Co. LLC 9400 Lurline Ave Unit B-1 Chatsworth , CA 91311 United States daniel@humblejuiceco.com info@humblejuiceco.com Issuing Office: Center for Tobacco Products United States Dear Daniel Clark: The United States Food and Drug Administration’s (FDA) Center for Tobacco Products has completed an evaluation of your corrective actions included in your response dated June 20, 2019, in response to our Warning Letter dated June 7, 2019. Based on our evaluation, it appears that you have taken steps to address the violations contained in the Warning Letter regarding the Instagram account of Parker Hornday (pvrkerr), https://www.instagram.com/pvrkerr, containing social media posts with labeling and/or advertising for e-liquid products on behalf Humble Juice Co. LLC, as well as the Instagram account of Humble Juice Co. LLC (https://www.instagram.com/humblejuiceco), the Facebook account for Humble Juice Co. LLC (https://www.facebook.com/humblejuiceco), the Twitter account for Humble Juice Co. LLC (https://twitter.com/HumbleJuiceCo), and the website https://www.humblejuiceco.com. This letter does not relieve you or your firm from the responsibility of taking all necessary steps to ensure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. This letter also will not preclude any regulatory action should violations be observed in the future. Sincerely, /S/ David Rice Branch Chief Division of Promotion, Advertising, and Labeling Office of Compliance and Enforcement Center for Tobacco Products VIA Electronic Mail Attn: Will Woodlee wwoodlee@kkblaw.com Content current as of: 04/26/2021 Regulated Product(s) Tobacco